Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Zoetis Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.32, while Zoetis Inc trades at $73.09 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| KOLD | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $156.76 |
52-Week Low | $13.58 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD, an inverse ETF tracking natural gas futures, trades at $28.34, down 1.05% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. Recent news highlights natural gas price volatility driven by weather forecasts and LNG export fluctuations, with the ETF positioned as a tactical tool for traders amid market swings.
The outlook for KOLD hinges on continued natural gas price volatility, offering short-term trading opportunities but carrying high risk due to its leveraged structure. Key risks include rapid price reversals in natural gas and macroeconomic shifts affecting energy demand, requiring careful risk management for investors.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
